Drug to help prevent and treat cytokine release syndrome
Treatments studied
Part of Immune system & allergy clinical trials.
This Phase 1/2 trial tests CTO1681 to help prevent and treat cytokine release syndrome (CRS) in people with DLBCL who are receiving CD19 CAR T-cell therapy. CRS is a potentially serious immune reaction that can happen after CAR T treatment, and this study aims to make that complication less severe or easier to manage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are planning to get CAR T-cell therapy for DLBCL (axicabtagene ciloleucel or lisocabtagene maraleucel) and you are not receiving steroid prevention for CRS/ICANS.
- Your DLBCL has come back or did not respond after at least one prior standard treatment.
- Your heart, kidney, liver, and blood counts meet study thresholds (including adequate kidney function, safe heart pumping, and minimum blood counts).
- Your lymphoma must be measurable on scans, and your general health is good enough (ECOG 0 to 1).
- You can sign consent (or your legal representative can), and you follow birth-control rules if you can become pregnant or if you are a male participant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a rescue medicine given to treat severe immune over-reactions that can happen after CAR T cell therapy, such as cytokine release syndrome and an HLH-like syndrome. It may help calm the immune response if you are already enrolled in a specific CAR T study.
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
This Phase 2 study compares a “point-of-care” CAR T-cell treatment made at the hospital right away versus standard commercial CAR T-cells. It’s for adults with relapsed or refractory large B-cell lymphoma (a type of blood cancer) to see which approach works best and is safe.
This trial tests a new drug called TRS005 for people with a specific type of lymphoma (CD20-positive DLBCL) that has come back or not responded to at least two prior treatments. It is for those who cannot have a stem cell transplant and aims to see if the drug can shrink tumors and help control the disease.
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
Hear when a new Cytokine Release Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.